Lipocine Inc. (LPCN)
NASDAQ: LPCN · IEX Real-Time Price · USD
6.04
+0.39 (6.90%)
Jul 22, 2024, 11:39 AM EDT - Market open
Lipocine Employees
Lipocine had 17 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$277,139
Profits / Employee
-$527,543
Market Cap
31.07M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
Rapid Micro Biosystems | 193 |
Evogene | 142 |
Pluri | 134 |
Spectral AI | 78 |
NKGen Biotech | 63 |
MiNK Therapeutics | 31 |
Daré Bioscience | 26 |
LPCN News
- 27 days ago - Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study - PRNewsWire
- 6 weeks ago - Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 - PRNewsWire
- 2 months ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 - PRNewsWire
- 2 months ago - Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 - PRNewsWire
- 2 months ago - Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 - PRNewsWire
- 3 months ago - Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity - PRNewsWire
- 4 months ago - Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis - PRNewsWire
- 4 months ago - Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - PRNewsWire